Last updated: July 29, 2026
Boehringer Ingelheim v. USV Private Limited (1:25-cv-00862): Litigation Summary, Claims at Issue, and Likely Patent-Validity and Infringement Postures
Executive summary: The docket 1:25-cv-00862 is a pending Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) patent infringement case against USV Private Limited. The action is at an early stage with limited publicly visible information in the record available for analysis here. A complete litigation summary tied to the specific asserted patents, claim construction posture, validity theories, injunction/settlement posture, and schedule cannot be produced from the provided input alone.
What is Boehringer Ingelheim Pharmaceuticals Inc. v. USV Private Limited 1:25-cv-00862 about?
Short answer: A patent infringement dispute brought by BIPI against USV Private Limited, filed in the U.S. District Court under case number 1:25-cv-00862.
What court, what procedural posture, and what stage is the case in?
To produce an accurate procedural-stage summary (complaint date, answer date, early Rule 12 motions, Markman timeline, amendment schedule, and trial/PI calendar), the case-specific docket entries and filings must be cited. Those details are not included in the prompt, so a complete summary cannot be generated.
Which patents are asserted in 1:25-cv-00862?
Short answer: Not determinable from the provided information.
How many asserted patents and what patent families usually appear in this type of filing?
A correct count and family breakdown requires the complaint exhibit listing asserted Orange Book patents or the “Asserted Patents” section in the complaint and subsequent scheduling order.
What is USV’s likely infringement and invalidity strategy in Boehringer Ingelheim v. USV Private Limited?
Short answer: Not determinable without the asserted claims/patents and the responsive pleadings.
Typical posture in Paragraph IV / Hatch-Waxman-type cases
Common defenses include non-infringement, invalidity under 35 U.S.C. §§ 101, 102, 103, and 112, and non-enablement/indefiniteness. But mapping these to this case requires the actual arguments USV raised (Answer, MTDs, invalidity contentions, and claim construction briefing).
Has USV filed a motion to dismiss, and what issues would it target?
Short answer: Not determinable from the provided information.
What motions are normally filed early
Typical early motions include lack of standing, failure to state a claim, improper venue, and sometimes Rule 12 challenges tied to the statutory basis of a Hatch-Waxman infringement action. The presence or absence of such motions cannot be asserted without docket text.
What claim construction issues are likely to drive the outcome?
Short answer: Not determinable from the provided information.
What to look for in a claim-construction fight
For drug patents, claim-construction disputes often center on:
- process parameters and ranges
- component definitions (e.g., purity thresholds, particle size, excipient identity)
- method steps and ordering
- “effective amount”/functional limitations
But the asserted patent types in this case (composition, method-of-use, formulation/process) are unknown from the prompt, so a claims-and-limitations analysis cannot be correctly tied to the docket.
What is the injunction posture in 1:25-cv-00862?
Short answer: Not determinable from the provided information.
Preliminary injunction vs. permanent injunction
In generic or ANDA-related patent cases, injunctive relief can depend on:
- merits stage (PI motion timing)
- launch risk
- likelihood of infringement and validity
These are fact- and order-dependent and cannot be produced without docket filings.
What are the key validity theories in Boehringer Ingelheim’s asserted patents?
Short answer: Not determinable from the provided information.
What usually drives validity contentions
Invalidity contentions frequently leverage:
- anticipation and obviousness based on prior art references
- obviousness combinations for formulations and methods
- indefiniteness for functional claiming
- enablement issues for broad genus claiming
No asserted patents or claim numbers are provided, so the analysis cannot be grounded.
What does the settlement or consent judgment landscape look like for this docket?
Short answer: Not determinable from the provided information.
What you’d normally track
Settlement agreements are reflected through:
- stipulated dismissals
- consent judgments
- modified launch dates
- covenant-not-to-sue terms
None of those docket outcomes are included in the prompt.
What is the Orange Book status tied to this litigation?
Short answer: Not determinable from the provided information.
Orange Book mapping needed for accurate analysis
To answer Orange Book status, this requires identifying:
- the branded drug name and NDA holder
- the ANDA applicant and the paragraph IV letter
- the specific Orange Book-listed patents and their listed expiration dates
- any exclusivity (3-year, 5-year, pediatric, non-patent exclusivities)
No drug/NDA/ANDA identifiers are provided.
How does Boehringer Ingelheim’s patent estate compare against USV’s entry risk?
Short answer: Not determinable from the provided information.
Business-impact model that requires asserted-patent dates
A litigation and exclusivity-risk comparison needs:
- earliest relevant patent expiration
- 180-day exclusivity position (if any)
- stay status under 21 U.S.C. § 355(j)
- any design-around pathways
Those inputs are not supplied.
Key procedural milestones and dates (what matters for investors and litigators)
Short answer: Not determinable from the provided information.
Milestones typically used in docket analytics
- complaint filing date; service and answer deadlines
- Rule 26(f) discovery plan
- infringement and validity contentions exchange
- Markman hearing date
- expert discovery and rebuttal expert deadlines
- dispositive motion schedule
- trial date or settlement-trigger windows
No dates or docket entries are provided.
Claims-at-issue and parties (who must prove what)
Short answer: Not determinable from the provided information.
Who typically bears burden
- Plaintiff: prove infringement for each asserted claim by a preponderance of evidence and prove validity by clear and convincing evidence when validity is challenged.
- Defendant: prove invalidity (and non-infringement) for each asserted claim.
But the “each asserted claim” set is missing.
What generic entry risks exist for USV related to this litigation?
Short answer: Not determinable from the provided information.
Launch timing depends on stays and exclusivities
Whether USV can launch depends on:
- automatic 30-month stay (if an ANDA triggers it)
- dismissal/settlement timing
- court rulings on preliminary injunction or final merits
- any appellate stays
No ANDA context is provided.
Key Takeaways
- The docket 1:25-cv-00862 is an active Boehringer Ingelheim Pharmaceuticals Inc. v. USV Private Limited patent case.
- A litigation summary that identifies asserted patents, claims, validity/infringement positions, scheduling, and legal theories cannot be accurately produced from the provided input alone.
- A complete, decision-grade analysis requires the complaint and subsequent docket filings that list asserted patents and reflect the procedural history.
FAQs
- What is the statutory basis for Boehringer Ingelheim v. USV Private Limited (1:25-cv-00862)?
- Which Orange Book patents does the complaint assert in 1:25-cv-00862?
- Has USV filed a Paragraph IV challenge letter or an ANDA-related defense in this docket?
- What is the current schedule for claim construction, experts, and trial in 1:25-cv-00862?
- Did the case result in a stipulated dismissal, consent judgment, or settlement agreement?
References (APA)
- U.S. District Court docket, Boehringer Ingelheim Pharmaceuticals Inc. v. USV Private Limited, Case No. 1:25-cv-00862.
